

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Confirmation No.: 4326
HO <i>et al.</i>	Art Unit: 1651
Appl. No.: 09/960,244	Examiner: Leon B. Lankford, Jr.
Filed: September 21, 2001	Atty. Docket: 2560.0020000/JAG/D-S
For: Cell Populations Which Co-Express CD49c and CD90	

Supplemental Amendment and Reply Under 37 C.F.R. § 1.111(a)(2)(B)

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In further reply to the Office Action mailed October 5, 2007, Applicants' interview with the Examiner on April 3, 2008, and the Examiner's email correspondence of June 11, 2008, Applicants submit herein a claim amendment (new claim 97), as suggested by the Examiner, and discuss why this claim should be allowed.

Amendments to the Claims begin on Page 2.

Remarks begin on Page 4.

Exhibits A through G are attached hereto.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefore (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.